A prospective observational study on efficacy of modified rheumatoid arthritis protocol of rituximab (2000 mg) on patients of pemphigus


  • Santosh Kumar Singh Department of Skin VD and Leprosy, B. R. D. Medical College, Gorakhpur, India
  • Prannav Satyaraj Department of Skin VD and Leprosy, B. R. D. Medical College, Gorakhpur, India
  • Prasoon Sachan Department of Skin VD and Leprosy, B. R. D. Medical College, Gorakhpur, India




Pemphigus, Rituximab, B lymphocyte, Complete remission


Background: Rituximab (RTX), an anticluster of differentiation 20 antibody, targets B lymphocytes, has been shown in open series studies to be effective in treating pemphigus. The objective was to evaluate whether a modified rheumatoid arthritis protocol, in which the patient received four doses of 500 mg of rituximab at an interval of two weeks was safe and effective in pemphigus management.

Methods: It was a prospective observational study in which 46 pemphigus patients included and four doses of 500 mg of RTX at an interval of two weeks given and number of doses required for complete remission (CR), proportion of patient respond partially or doesn’t respond or relapsed after CR.

Results: We enrolled 46 patients in the study, 8 with pemphigus foliaceus (PF) and 38 with pemphigus vulgaris (PV). 20 were male and 26 were female followed up for 15±4.24 months (12-18). All patient responded to therapy. CR of 23 patient after 2 dose OF 500 mg RTX ,of 18 patient after 3 dose, 5 patient partial remission (PR) after 4 doses. All patient were on 100 mg OD azathioprine. PR, all have oral lesions got CR after 3 weeks of 4th dose. 3 patients relapsed MD 11±2.8 months (9-13 months)  and given additional dose of 500 mg RTX and got resolved in 3 weeks.

Conclusions: We found modified rheumatic arthritis protocol for RTX was shown to be effective in treatment of pemphigus patient and relapse cases with additional dose. Immunological assay were not performed to limit the study.



Amagai M. Dermatology. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Mosby; 2012: 461-74.

Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67(5):869-77.

Koch PJ, Walsh MJ, Schmelz M, Goldschmidt MD, Zimbelmann R, Franke WW. Identification of desmoglein, a constitutive desmosomal glycoprotein, as a member of the cadherin family of cell adhesion molecules. Eur J Cell Biol. 1990;53(1):1-12.

Lever WF, Schaumburg‑Lever G. Immuno-suppressant’s and prednisone in pemphigus vulgaris:Therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977;113(9):1236-41.

Pasricha JS. Pulse therapy as a cure for autoimmune diseases. Indian J Dermatol Venereol Leprol. 2003;69:323-8.

Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66(2):142-4.

Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: Therapeutic effects beyond B-cell depletion. J Invest Dermatol. 2008;128(12):2745-7.

Boulard C, Lehembre SD, Picard‐Dahan C, Kern JS, Zambruno G, Feliciani C. Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. British J Dermatol. 2016;175(1)142-9.

Singh R, Pandhi RK. A clinicopathological study of Pemphigus. Indian J Dermatol Venereol Leprol. 1973;39(3):126.

Sehgal VN. Pemphigus in India. A note. Indian J Dermatol. 1972;18(1):5-7.

Mascarenhas MF, Hede RV, Shukla P, Nadkarni NS, Rege VL. Pemphigus in Goa. J Indian Med Assoc. 1994;92(10):342-3.

Kanwar AJ, Ajith AC, Narang T. Pemphigus in North India. J Cutan Med Surg. 2006;10(1):21-5.

Kanwar A, De D. Pemphigus in India. Indian J Dermatol Venereol Leprol. 2011;77(4):439.

Kanwar AJ, Tsuruta D, Vinay K, Koga H, Ishii N, Dainichi T, et al. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol. 2013;27(1):1‑7.

Sharma V, Bhari N, Gupta S, Sahni K, Khanna N, Ramam M, et al. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study. Indian J Dermatol Venereol Leprol. 2016;82(4):389‑94.

Londhe P, Khopkar U, Kalyanpad Y. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus. Indian J Dermatol Venereol Leprol. 2014;80(4):300-5.

Khopkar US, Chadha AA, Nitya MS, Lahoria V. Follow‑up data of rituximab as adjuvant therapy in pemphigus. Indian J Dermatol. 2017;62(6):671‑3.

Ahmed AR, Shetty S. The emerging role of rituximab in autoimmune blistering diseases. Am J Clin Dermatol. 2015;16(3):167-77.

Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166(2):405-12.

Kanwar AJ, Vinay K, Sawatkar GU, Dogra S, Minz RW, Shear NH, et al. Clinical and immunological outcomes of high and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170(6):1341-9.

Gupta J, Raval RC, Shah AN, Solanki RB, Patel DD, Shah KB, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venereol Leprol. 2017;83(3):317-25.

Cianchini G, Lupi F, Masini C, Corona R, Puddu P, DePità O. Therapy with rituximab for autoimmune pemphigus: results from a single centre observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67(4):617-22.

Wang HH, Liu CW, Li YC, Huang YC. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928-32.

Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165(3):646-5.

Chen DM, Odueyungbo A, Csinady E, Gearhart L, Lehane P, Cheu M, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020;182(5):1111-9.

Gopaluni S, Smith RM, Lewin M, McAlear CA, Mynard K, Jones RB, et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody- associated vasculitis (Ritazarem): study protocol for a randomized controlled trial. Trials. 2017;18(1):112.

Vinay K, Kanwar AJ, Mittal A, Dogra S, Minz RW, Hashimoto T. Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris. JAMA Dermatol. 2015;151((8):878‑82.

Joly P, Maho‑Vaillant M, Prost‑Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First‑line rituximab combined with short‑term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel‑group, open‑label randomised trial. Lancet. 2017;389(10083):2031‑40.






Original Research Articles